Viz.ai® Announces Three New Studies Supporting Viz HCM™ Module for the Detection and Management of Suspected Hypertrophic Cardiomyopathy
Retrieved on:
Wednesday, April 3, 2024
Health, Technology, Hospitals, Health Technology, Software, Artificial Intelligence, Cardiology, Deep learning, FACC, Harvard Medical School, Machine learning, Cone Health Women's Hospital, PPV, Innovation, Algorithm, Artificiality, Assistant, Disease, Associate, Patient, Atlantic Health System, Triage, Salem Hospital, AI, Viz, American College, Massachusetts General Hospital, HCM, Hospital, Hypertrophic cardiomyopathy, Senior counsel, Sports cardiology, Hypertrophy, Medical director, Probability, FDA, ACC, ECG, Mass, Medical imaging
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.
Key Points:
- Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.
- The Viz HCM module is the first and only AI algorithm cleared by the FDA for HCM.
- The study found that Viz HCM performance in suspected HCM detection was consistent across various racial backgrounds with a sensitivity of 68.4% and specificity of 99.1%.
- This validates the effectiveness of relevance score sorting for prioritizing higher probability HCM-positive patients identified by deep-learning algorithms analyzing ECG data.